We represented axialHealthcare, a care optimization platform navigating substance use issues for patients, providers, and health plans, in a $15 million Series C round of financing to accelerate its expansion into the substance use disorder (SUD) treatment, and recovery sector. Previous institutional investors Oak HC/FT, .406 Ventures, BlueCross BlueShield Venture Partners (BCBSVP), and Sandbox Advantage Fund led the round.
axialHealthcare Closes Series C Funding Round
Client Type: Private Company
You Also May Be Interested In:
Representation of AutoZone, Inc. (NYSE: AZO) in a public offering of $500,000,000 of 3.625% Senior Notes due 2025 and $750,000,000 of 4.000% Senior Notes due 2030
Representation of Life Sciences Company Fagron Holding USA LLC